Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VBI-2901a in Healthy Adults Previously Vaccinated With COVID-19 Vaccines
NCT05548439Phase 1Completed
- Sponsor
- VBI Vaccines Inc.
- Start
- Oct 2022
- Primary completion
- Jan 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VBI-2901a in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by VBI Vaccines Inc. Primary endpoints: Local reactions (solicited adverse events) at 7 days, Systemic reactions (solicited adverse events) at 7 days and 4 more. Started Oct 2022; status: completed.
02
Drugs
VBI-2901a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05548439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548439.